Search results for "yo"

showing 10 items of 16837 documents

914 Contrast enhanced live 3D echo in acute myocardial infarction determines accurate left ventricular wall motion and volumes compared to cardiac MR…

2003

medicine.medical_specialtymedicine.diagnostic_testbusiness.industrymedia_common.quotation_subjectEcho (computing)Electrocardiography in myocardial infarctionMagnetic resonance imagingGeneral Medicinemedicine.diseaseMr imagingInternal medicinemedicineCardiologyContrast (vision)Radiology Nuclear Medicine and imagingMyocardial infarctionCardiology and Cardiovascular MedicinebusinessLeft ventricular wall motionmedia_commonEuropean Journal of Echocardiography
researchProduct

The Sum of ST-Segment Elevation Is the Best Predictor of Microvascular Obstruction in Patients Treated Successfully by Primary Percutaneous Coronary …

2010

Introduction and objectives The usefulness of ST-segment elevation resolution (STR) for predicting epicardial reperfusion is well established. However, it is still not clear how ST-segment changes are related to microvascular obstruction (MVO) observed by cardiovascular magnetic resonance (CMR) after primary percutaneous coronary intervention (pPCI) for ST-segment elevation myocardial infarction (STEMI). Methods The study involved 85 consecutive patients admitted for a first STEMI and treated by pPCI who had a patent infarct-related artery. An ECG was recorded on admission and 90 min and 6, 24, 48 and 96 h after pPCI. Thereafter, STR and the sum of ST-segment elevation (sumSTE) in all leads…

medicine.medical_specialtymedicine.diagnostic_testbusiness.industrymedicine.medical_treatmentPercutaneous coronary interventionMagnetic resonance imagingGeneral MedicineOdds ratiomedicine.diseaseRevascularizationConfidence intervalmedicine.anatomical_structureInternal medicinemedicineCardiologyST segmentcardiovascular diseasesMyocardial infarctionbusinesshuman activitiesArteryRevista Española de Cardiología (English Edition)
researchProduct

Protrhombotic Effects of Contraceptives

2010

The use of oral contraceptives first became widespread some 40 years ago, and reports of an excess risk of cardiovascular disease among women who used these agents soon followed. Few drugs have been the object of such intensive epidemiological research, the outcome of which has provided clinicians with detailed information about risks not only of specific thrombotic diseases but also important non-contraceptive benefits from the pill. Recently, oral contraceptives have been classified by some according to "generation" (first, second, third, and most recently, fourth generation): first-generation formulations containing lynestrenol or norethindrone, second-generation formulations containing …

medicine.medical_specialtymedicine.drug_classLipid Metabolism DisordersMyocardial InfarctionPhysiologyGestodeneRisk AssessmentRisk FactorsDesogestrelInternal medicineDrug DiscoverymedicineHumansLevonorgestrelGlucose Metabolism DisordersVenous ThrombosisPharmacologyHemostasisbusiness.industryModels CardiovascularAtherosclerosisLipid MetabolismNorgestimateSettore MED/11 - Malattie Dell'Apparato CardiovascolareLynestrenolEndocrinologyEstrogenPillHypertensionFemaleRisk assessmentbusinessTrhombosis contraceptivesContraceptives Oralmedicine.drugCurrent Pharmaceutical Design
researchProduct

Adult stem cells in the human endometrium

2009

medicine.medical_specialtymedicine.drug_classMesenchymal stem cellEndometriosisMyometriumBiologymedicine.diseaseAndrologyEndocrinologyEstrogenInternal medicinemedicineCD146Stem cellFetal Stem CellsAdult stem cell
researchProduct

FLT3 as a therapeutic target in AML: still challenging after all these years

2010

Abstract Mutations within the FMS-like tyrosine kinase 3 (FLT3) gene on chromosome 13q12 have been detected in up to 35% of acute myeloid leukemia (AML) patients and represent one of the most frequently identified genetic alterations in AML. Over the last years, FLT3 has emerged as a promising molecular target in therapy of AML. Here, we review results of clinical trials and of correlative laboratory studies using small molecule FLT3 tyrosine kinase inhibitors (TKIs) in AML patients. We also review mechanisms of primary and secondary drug resistance to FLT3-TKI, and from the data currently available we summarize lessons learned from FLT3-TKI monotherapy. Finally, for using FLT3 as a molecul…

medicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentImmunologyBiologyBiochemistryTyrosine-kinase inhibitorTargeted therapychemistry.chemical_compoundfluids and secretionshemic and lymphatic diseasesInternal medicinemedicineHumansProtein Kinase InhibitorsQuizartinibHematologyMyeloid leukemiaCancerhemic and immune systemsCell BiologyHematologymedicine.diseaseLeukemia Myeloid Acutefms-Like Tyrosine Kinase 3chemistryDrug Resistance Neoplasmembryonic structuresCancer researchTyrosine kinaseCrenolanibBlood
researchProduct

Type 1 or Type 2 Myocardial Infarction in Patients with a History of Coronary Artery Disease: Data from the Emergency Department

2019

A type 2 myocardial infarction (T2MI) is the result of an imbalance between oxygen supply and demand, without acute atherothrombosis. T2MI is frequent in emergency departments (ED), but has not been extensively evaluated in patients with previously known coronary artery disease (CAD). Our study assessed the incidence and characteristics of T2MI compared to type 1 (T1MI) in CAD patients admitted to an ED. Among 33,669 consecutive patients admitted to the ED, 2830 patients with T1MI or T2MI were systematically included after prospective adjudication by the attending clinician according to the universal definition. Among them, 619 (22%) patients had a history of CAD. Using multivariable analys…

medicine.medical_specialtymedicine.medical_treatment030204 cardiovascular system & hematologyArticletype 2 myocardial infarctionCoronary artery disease03 medical and health sciences0302 clinical medicineInternal medicinemedicine030212 general & internal medicineMyocardial infarctionhospital mortalitybiologybusiness.industryC-reactive proteinPercutaneous coronary interventionGeneral MedicineOdds ratioEmergency departmentmedicine.diseaseTroponinConfidence intervalmyocardial infarctionCardiologybiology.proteinbusinesscoronary artery diseaseJournal of Clinical Medicine
researchProduct

Impact of overlapping on 1-year clinical outcomes in patients undergoing everolimus-eluting bioresorbable scaffolds implantation in routine clinical …

2016

Background Overlapping implantation of bioresorbable scaffolds (BRSs) are frequent in long coronary lesions. Its impact on clinical outcomes is unknown. Objective: To compare the clinical outcomes of patients treated with overlapping BRS with those patients treated with no-overlap BRS. Methods: We analyzed the 1-year clinical outcomes of 1,477 patients treated with BRS in the GHOST-EU registry, according to the implantation of overlapping BRS. Primary endpoint was patient oriented composite endpoint (PoCE) of: all-cause death, any myocardial infarction (MI) and any repeated revascularization. Scaffold thrombosis, according to Academic Research Consortium definition, was also analyzed. Resul…

medicine.medical_specialtymedicine.medical_treatment030204 cardiovascular system & hematologyRevascularizationCoronary artery diseaseLesion03 medical and health sciences0302 clinical medicineInternal medicinemedicineClinical endpointRadiology Nuclear Medicine and imaging030212 general & internal medicineMyocardial infarctionEverolimusbusiness.industryfungiPercutaneous coronary interventionGeneral Medicinemedicine.diseaseThrombosisCardiologymedicine.symptomCardiology and Cardiovascular Medicinebusinessmedicine.drugCatheterization and Cardiovascular Interventions
researchProduct

Management of refractory angina: an update.

2020

Abstract Despite the use of anti-anginal drugs and/or percutaneous coronary interventions (PCI) or coronary artery bypass grafting, the proportion of patients with coronary artery disease who have daily or weekly angina ranges from 2% to 24%. Refractory angina refers to long-lasting symptoms (for >3 months) due to established reversible ischaemia, which cannot be controlled by escalating medical therapy with the use of 2nd- and 3rd-line pharmacological agents, bypass grafting, or stenting. While there is uncertain prognostic benefit, the treatment of refractory angina is important to improve the quality of life of the patients affected. This review focuses on conventional pharmacolog…

medicine.medical_specialtymedicine.medical_treatmentChronic coronary syndromeStemcell therapyCoronary Artery Disease030204 cardiovascular system & hematologyRevascularizationAngina PectorisAnginaCoronary artery disease03 medical and health sciencesCoronary artery bypass surgery0302 clinical medicinePercutaneous Coronary InterventionRestenosisInternal medicinemedicineMyocardial RevascularizationHumanscardiovascular diseases030212 general & internal medicineCoronary Artery BypassCoronary sinusbusiness.industryPercutaneous coronary interventionAnginamedicine.diseaseRadiation therapyChronic total occlusionSpinal cord stimulationConventional PCICardiologyQuality of LifeCardiology and Cardiovascular MedicinebusinessEuropean heart journal
researchProduct

Cardiac pacemaker function of HCN4 channels in mice is confined to embryonic development and requires cyclic AMP.

2008

Important targets for cAMP signalling in the heart are hyperpolarization-activated and cyclic nucleotide-gated (HCN) channels that underlie the depolarizing 'pacemaker' current, I(f). We studied the role of I(f) in mice, in which binding of cAMP to HCN4 channels was abolished by a single amino-acid exchange (R669Q). Homozygous HCN4(R669Q/R669Q) mice die during embryonic development. Prior to E12, homozygous and heterozygous embryos display reduced heart rates and show no or attenuated responses to catecholaminergic stimulation. Adult heterozygous mice display normal heart rates at rest and during exercise. However, following beta-adrenergic stimulation, hearts exhibit pauses and sino-atrial…

medicine.medical_specialtymedicine.medical_treatmentCyclic Nucleotide-Gated Cation ChannelsEmbryonic DevelopmentStimulationMice TransgenicBiologyIn Vitro TechniquesGeneral Biochemistry Genetics and Molecular BiologyCardiac pacemakerArticleMiceHeart RatePregnancyInternal medicineHeart ratemedicineCyclic AMPHyperpolarization-Activated Cyclic Nucleotide-Gated ChannelsAnimalsMyocytes CardiacMolecular BiologyIon channelCells CulturedCatecholaminergicGeneral Immunology and MicrobiologyGeneral NeuroscienceEmbryogenesisDepolarizationEmbryoHeartMice Inbred C57BLEndocrinologyMutationFemaleThe EMBO journal
researchProduct

Treatment decision making in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy: State of the art

2014

No abstract available

medicine.medical_specialtymedicine.medical_treatmentDecision MakingCardiomyopathySudden deathImplantable cardioverter-defibrillatorAntiarrhythmic drugs; Cardiac transplantation; Implantable cardioverter-defibrillator; Management; Radiofrequency catheter ablation; Sudden death; Arrhythmogenic Right Ventricular Dysplasia; Decision Making; HumansAntiarrhythmic drugs; Cardiac transplantation; Implantable cardioverter-defibrillator; Management; Radiofrequency catheter ablation; Sudden deathInternal medicinemedicineHumansIn patientIntensive care medicineArrhythmogenic Right Ventricular DysplasiaRadiofrequency catheter ablationbusiness.industrySudden deathImplantable cardioverter-defibrillatormedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareArrhythmogenic right ventricular dysplasiaAntiarrhythmic drugsManagementAntiarrhythmic drugRadiofrequency catheter ablationCardiologyCardiac transplantationTreatment decision makingCardiology and Cardiovascular Medicinebusiness
researchProduct